Latest Insider Transactions at Ironwood Pharmaceuticals Inc (IRWD)
This section provides a real-time view of insider transactions for Ironwood Pharmaceuticals Inc (IRWD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IRONWOOD PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IRONWOOD PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
3,282
+2.11%
|
-
|
|
Aug 12
2024
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.36%
|
$39,640
$4.27 P/Share
|
|
Aug 12
2024
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,107
-1.92%
|
$12,428
$4.27 P/Share
|
|
Jun 18
2024
|
Mark G Currie |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+4.1%
|
-
|
|
Jun 18
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+14.04%
|
-
|
|
Jun 18
2024
|
Marla L Kessler |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+16.74%
|
-
|
|
Jun 18
2024
|
Julie Mc Hugh |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+12.92%
|
-
|
|
Jun 18
2024
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+25.0%
|
-
|
|
Jun 18
2024
|
Jon R Duane |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+14.33%
|
-
|
|
Jun 18
2024
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+11.44%
|
-
|
|
Jun 18
2024
|
Jay Shepard |
BUY
Grant, award, or other acquisition
|
Direct |
24,311
+16.11%
|
-
|
|
Jun 15
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
2,572
+2.02%
|
-
|
|
Jun 10
2024
|
Julie Mc Hugh |
SELL
Open market or private sale
|
Direct |
22,766
-14.03%
|
$136,596
$6.29 P/Share
|
|
Jun 07
2024
|
Catherine Moukheibir |
SELL
Open market or private sale
|
Direct |
35,574
-42.25%
|
$213,444
$6.61 P/Share
|
|
Jun 06
2024
|
Catherine Moukheibir |
SELL
Open market or private sale
|
Direct |
44,426
-34.54%
|
$266,556
$6.36 P/Share
|
|
May 20
2024
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,404
-5.58%
|
$104,424
$6.45 P/Share
|
|
May 20
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
16,128
-3.75%
|
$96,768
$6.45 P/Share
|
|
May 20
2024
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
22,725
-7.31%
|
$136,350
$6.45 P/Share
|
|
May 20
2024
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
67,618
-5.55%
|
$405,708
$6.45 P/Share
|
|
May 16
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,280
-5.39%
|
$109,680
$6.64 P/Share
|
|
Mar 15
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,662
+1.34%
|
-
|
|
Mar 08
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
120,298
+8.99%
|
-
|
|
Mar 08
2024
|
Andrew Davis SVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,120
+10.67%
|
-
|
|
Mar 08
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Exercise of conversion of derivative security
|
Direct |
34,936
+7.52%
|
-
|
|
Mar 08
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,120
+9.87%
|
-
|
|
Mar 08
2024
|
Minardo John Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,752
+9.5%
|
-
|
|
Mar 06
2024
|
Jon R Duane |
BUY
Open market or private purchase
|
Direct |
6,920
+5.41%
|
$55,360
$8.7 P/Share
|
|
Mar 05
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
264,876
+19.44%
|
-
|
|
Mar 04
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,684
+3.42%
|
$96,156
$9.38 P/Share
|
|
Feb 12
2024
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,427
+16.31%
|
-
|
|
Feb 12
2024
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
47,380
-17.41%
|
$710,700
$15.24 P/Share
|
|
Feb 12
2024
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,213
+14.42%
|
-
|
|
Feb 12
2024
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,908
-5.56%
|
$118,620
$15.24 P/Share
|
|
Feb 12
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
54,427
+12.11%
|
-
|
|
Feb 12
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
38,618
-10.19%
|
$579,270
$15.24 P/Share
|
|
Feb 12
2024
|
Andrew Davis SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,312
+19.27%
|
-
|
|
Feb 12
2024
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,846
-4.51%
|
$147,690
$15.24 P/Share
|
|
Feb 12
2024
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
177,164
-17.54%
|
$2,657,460
$15.24 P/Share
|
|
Feb 12
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,312
+18.33%
|
-
|
|
Feb 08
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,332
-15.48%
|
$578,648
$14.9 P/Share
|
|
Jan 17
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+24.14%
|
-
|
|
Jan 17
2024
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,981
+22.71%
|
-
|
|
Jan 17
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
57,971
+13.26%
|
-
|
|
Jan 17
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
249,617
+19.82%
|
-
|
|
Dec 15
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,572
+1.21%
|
-
|
|
Dec 15
2023
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,347
+1.11%
|
-
|
|
Dec 14
2023
|
Marla L Kessler |
SELL
Open market or private sale
|
Direct |
9,926
-9.32%
|
$109,186
$11.19 P/Share
|
|
Nov 20
2023
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,287
-1.49%
|
$29,583
$9.69 P/Share
|
|
Nov 16
2023
|
Sravan Kumar Emany SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,661
-3.53%
|
$59,949
$9.44 P/Share
|
|
Sep 15
2023
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
2,098
+1.62%
|
-
|